Trial Profile
A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability of Two RDEA3170 Tablets
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Verinurad (Primary)
- Indications Gout
- Focus Pharmacokinetics
- Sponsors Ardea Biosciences
- 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 15 Feb 2015 Planned End Date changed from 1 Feb 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
- 16 Jan 2015 New trial record